3,817 companies
12,975 AI summaries
9,784 risk analyses
5,404 growth scores
Register free — watchlist & alerts →
🔔 Get free email alerts on Kitazato Corporation (3680)
AI summaries of Japanese EDINET filings — in English. Free, unsubscribe anytime.
- ✓ Email alert when 3680 files its next EDINET disclosure
- ✓ AI summary · sentiment · risk · growth (JA / EN)
- ✓ Free account: watchlist & alerts on all the stocks you follow
EDINET 3680 Neutral Risk Analyzed
Kitazato Corporation
Extraordinary Report ／ 2026-11-13 17:00
Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).
M&A
AI Summary
2026-11-13 17:12
Kitazato Corporation resolved to establish FertiLink Co., Ltd., a subsidiary focused on reproductive medicine information, education and medical event management. Capitalized at ¥3M, to be 100% owned, launching December 2026.
KEY POINTS
- New subsidiary FertiLink Co., Ltd. established with ¥3M capital (100% Kitazato ownership)
- Qualifies as specified subsidiary; located in Minato Ward, Tokyo
- Business focuses on reproductive health education, medical event planning & management
📊 Revenue
N/A
💰 Operating profit
N/A
🔮 Outlook
Not stated
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
| Category | Description | Score | New |
|---|---|---|---|
| Customer Concentration Risk | Newly established subsidiary with unproven customer base; ability to acquire and retain clients in competitive medical education/event market presents concentration risk. | 5/10 | |
| Other Business Risk | FertiLink's reproductive medicine education business differs from Kitazato's core precision equipment operations, presenting execution and profitability risks for new venture. | 4/10 | |
| Regulatory Risk | Reproductive medicine information/education business subject to strict healthcare regulations; regulatory changes or compliance violations could impact operations. | 4/10 |
5/10
Customer Concentration Risk
Newly established subsidiary with unproven customer base; ability to acquire and retain clients in competitive medical education/event market presents concentration risk.
4/10
Other Business Risk
FertiLink's reproductive medicine education business differs from Kitazato's core precision equipment operations, presenting execution and profitability risks for new venture.
4/10
Regulatory Risk
Reproductive medicine information/education business subject to strict healthcare regulations; regulatory changes or compliance violations could impact operations.
Track Japanese disclosures with JSIGNAL
AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.
Start free — 30-day trial Login